CN110997709B - Ror1 car t-细胞 - Google Patents

Ror1 car t-细胞 Download PDF

Info

Publication number
CN110997709B
CN110997709B CN201880045348.9A CN201880045348A CN110997709B CN 110997709 B CN110997709 B CN 110997709B CN 201880045348 A CN201880045348 A CN 201880045348A CN 110997709 B CN110997709 B CN 110997709B
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
chain variable
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880045348.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110997709A (zh
Inventor
阿米特·纳什瓦尼
萨蒂恩·戈希尔
马可·德拉佩鲁塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of CN110997709A publication Critical patent/CN110997709A/zh
Application granted granted Critical
Publication of CN110997709B publication Critical patent/CN110997709B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN201880045348.9A 2017-07-05 2018-07-05 Ror1 car t-细胞 Active CN110997709B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1710836.6A GB201710836D0 (en) 2017-07-05 2017-07-05 ROR1 Car T-Cells
GB1710836.6 2017-07-05
PCT/GB2018/051915 WO2019008378A1 (en) 2017-07-05 2018-07-05 Ror1 car t-cells

Publications (2)

Publication Number Publication Date
CN110997709A CN110997709A (zh) 2020-04-10
CN110997709B true CN110997709B (zh) 2023-12-05

Family

ID=59592474

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880045348.9A Active CN110997709B (zh) 2017-07-05 2018-07-05 Ror1 car t-细胞

Country Status (9)

Country Link
US (1) US11723925B2 (https=)
EP (1) EP3649150B1 (https=)
JP (1) JP7179030B2 (https=)
CN (1) CN110997709B (https=)
AU (1) AU2018295478A1 (https=)
CA (1) CA3068197A1 (https=)
GB (1) GB201710836D0 (https=)
MX (1) MX2019015352A (https=)
WO (1) WO2019008378A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
CN108441505B (zh) * 2018-05-28 2023-07-07 上海恒润达生生物科技股份有限公司 一种靶向ror1的嵌合抗原受体及其用途
US12497453B2 (en) 2019-09-27 2025-12-16 Nanjing Immunophage Biotech Co., Ltd. ROR1 specific chimeric antigen receptors and their therapeutic applications
EP4200336A4 (en) * 2020-08-24 2024-09-25 Epimab Biotherapeutics (HK) Limited Anti-ror1 antibodies and related bispecific binding proteins
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
CN114133457B (zh) * 2021-12-08 2022-08-19 郑州源创吉因实业有限公司 一种靶向ror1和cd33的双特异性嵌合抗原受体(car)及其应用
CN118974090A (zh) * 2022-04-02 2024-11-15 山东先声生物制药有限公司 抗ror1的抗体及其用途
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN118440200B (zh) * 2023-04-21 2025-05-16 星奕昂(上海)生物科技有限公司 靶向ror1的抗体及其应用
WO2025006880A1 (en) * 2023-06-29 2025-01-02 Caribou Biosciences, Inc. Diagnostic and therapeutic methods for use with ror1 antagonists
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016344A1 (en) * 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
WO2016115559A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016187216A1 (en) * 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0920798A (ja) * 1995-07-11 1997-01-21 Asahi Chem Ind Co Ltd ヒト抗ＨＢｓ抗体
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
PL1871805T3 (pl) * 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
CA2759733C (en) 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
NZ621170A (en) * 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES2657970T3 (es) 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos contra ROR1 de conejo/ser humano quiméricos
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
CN105283201B (zh) * 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
US10544201B2 (en) 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
WO2016039321A1 (ja) * 2014-09-08 2016-03-17 国立研究開発法人国立がん研究センター がん細胞特異的な抗体、抗がん剤、及びがんの検査方法
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
CA2963696A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
RU2021118125A (ru) * 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
CN107567445B (zh) 2015-02-02 2021-06-29 坎塞拉有限公司 可用作哺乳动物酪氨酸激酶ror1活性抑制剂的2-苯基-3h-咪唑并[4,5-b]吡啶衍生物
JP6542383B2 (ja) * 2015-04-14 2019-07-10 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗血管新生及び標的がん療法のための抗ｖｅｇｆｒ２ヒト抗体
WO2016187220A2 (en) 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
TW201734049A (zh) 2016-01-22 2017-10-01 健生生物科技公司 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
EP3481824B1 (en) 2016-07-11 2021-10-20 Kancera AB 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
US20200338210A1 (en) 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
JP2020521448A (ja) 2017-05-23 2020-07-27 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、およびｒｏｒ１またはｒｏｒ２に結合するタンパク質
AU2018289581C1 (en) 2017-06-23 2025-01-30 VelosBio Inc. ROR1 antibody immunoconjugates
US11987635B2 (en) 2017-06-25 2024-05-21 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Anti-4-1BB antibodies and methods of making and using thereof
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
US20210139579A1 (en) 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
EP3703711A4 (en) 2017-11-03 2021-01-13 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-MMR1 IMMUNOTHERAPY
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
US11723926B2 (en) * 2019-09-27 2023-08-15 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016344A1 (en) * 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
WO2016115559A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016187216A1 (en) * 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
嵌合抗原受体T细胞功能设计与运用的研究进展;支黎明等;《东南国防医药》;20170120(第01期);全文 *
嵌合抗原受体T细胞疗法及其在血液肿瘤免疫治疗中的应用;夏莉等;《上海交通大学学报(医学版)》;20170628(第06期);全文 *

Also Published As

Publication number Publication date
WO2019008378A1 (en) 2019-01-10
US20200405759A1 (en) 2020-12-31
CA3068197A1 (en) 2019-01-10
MX2019015352A (es) 2020-07-20
EP3649150A1 (en) 2020-05-13
EP3649150B1 (en) 2024-06-26
AU2018295478A1 (en) 2020-01-16
US11723925B2 (en) 2023-08-15
JP7179030B2 (ja) 2022-11-28
GB201710836D0 (en) 2017-08-16
CN110997709A (zh) 2020-04-10
JP2020529838A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
CN110997709B (zh) Ror1 car t-细胞
CN112789293B (zh) 针对cll1的单结构域抗体及其构建体
TWI718118B (zh) 針對ｒｏｒ１之特異性抗體及嵌合抗原受體
KR20220169488A (ko) 신규한 항원 결합 도메인 및 이를 포함하는 합성 항원 수용체
KR20220119621A (ko) Claudin18.2 결합 모이어티 및 이의 용도
JP2021525509A (ja) 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
KR20170120158A (ko) 항-dll3 키메라 항원 수용체 및 이의 사용 방법
WO2021121228A1 (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
CN110891972A (zh) 对ror1和cd3的双特异性抗体
CN116249559A (zh) 抗独特型组合物及其使用方法
JP2025508371A (ja) Ｓｔｅａｐ１に結合するキメラ抗原受容体
US20260035459A1 (en) Humanized chimeric antigen receptors targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
KR20220004087A (ko) 항체 개변 부위 인식 키메라 수용체
CN119613563A (zh) 编码car的核酸分子和含其的载体、car、含car的免疫细胞及其制造方法和含该细胞的医药组合物及提升细胞损伤活性的方法
HK40017255A (en) Ror1 car t-cells
HK40017255B (en) Ror1 car t-cells
EP4620974A1 (en) Anti-afp/hla02 tcr-like antibody and use thereof
US20240122980A1 (en) Use of tim-3 cytoplasmic tail in chimeric antigen receptors
Li et al. YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma
WO2023138661A1 (zh) Nkg2a抗体及其应用
WO2023078431A1 (zh) 一种特异性结合间皮素的合成t细胞受体抗原受体及其应用
HK40075690A (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
BR122024003787A2 (pt) Receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant